Secreted glycoprotein thrombospondin-2 (TSP-2) is a predictive biomarker of hepatocellular carcinoma (HCC) occurrence in chronic hepatitis C (CHC) patients after HCV elimination by direct-acting antiviral agents (DAAs). This evidence concerns the gene SCGN and chronic hepatitis C virus infection.